Axsome Therapeutics (AXSM) Total Non-Current Liabilities (2017 - 2026)

Axsome Therapeutics has reported Total Non-Current Liabilities for 9 years, with the latest figure at $585.3 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 29.24% year-over-year to $585.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $585.3 million (up 29.24% YoY) and the FY2025 annual result came in at $524.0 million, up 24.81% from the prior year.
• Total Non-Current Liabilities grew to $585.3 million in Q1 2026 per AXSM's latest filing, from $524.0 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $585.3 million in Q1 2026 and troughed at $136.0 million in Q2 2022.
• A 5-year average of $357.5 million and a median of $353.7 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities jumped 120.05% in 2023, then climbed 24.81% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $190.8 million in 2022, then surged by 69.77% to $324.0 million in 2023, then gained by 29.59% to $419.8 million in 2024, then gained by 24.81% to $524.0 million in 2025, then grew by 11.7% to $585.3 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $585.3 million, $524.0 million, and $505.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.